[{"id":9825,"date":"2026-01-29T19:29:19","date_gmt":"2026-01-29T18:29:19","guid":{"rendered":"https:\/\/www.egetis.com\/?page_id=9825"},"modified":"2026-03-24T13:49:07","modified_gmt":"2026-03-24T12:49:07","slug":"arsstamma-2026","status":"publish","type":"page","link":"https:\/\/www.egetis.com\/sv\/bolagsstyrning\/bolagsstamma\/arsstamma-2026\/","title":{"rendered":"\u00c5rsst\u00e4mma 2026"},"content":{"rendered":"<h3><strong>\u00c5rsst\u00e4mman 2026 kommer att h\u00e5llas den 14 april 2026 i Stockholm.<\/strong><\/h3>\n<h3><a href=\"https:\/\/www.egetis.com\/wp-content\/uploads\/Kallelse-1.pdf\">Kallelse<\/a><\/h3>\n<h3><a href=\"https:\/\/www.egetis.com\/wp-content\/uploads\/Fullmaktsformular-1.pdf\">Fullmaktsformul\u00e4r<\/a><\/h3>\n<h3><a href=\"https:\/\/www.egetis.com\/wp-content\/uploads\/Anmalan-och-formular-for-forhandsrostning-1.pdf\">Anm\u00e4lan och formul\u00e4r f\u00f6r f\u00f6rhandsr\u00f6stning<\/a><\/h3>\n<h3><a href=\"https:\/\/www.egetis.com\/wp-content\/uploads\/Valberedningens-forslag-och-motiverade-yttrande-1.pdf\">Valberedningens f\u00f6rslag och motiverade yttrande<\/a><\/h3>\n<h3><a href=\"https:\/\/www.egetis.com\/wp-content\/uploads\/Board-SHP-2026-1.pdf\">Board SHP 2026<\/a><\/h3>\n<h3><a href=\"https:\/\/www.egetis.com\/wp-content\/uploads\/Remuneration-report_Final_2025_SE.pdf\">Remuneration report_Final_2025_SE<\/a><\/h3>\n<h3><a href=\"https:\/\/www.egetis.com\/wp-content\/uploads\/Revisoryttrande-ABL-8-54-2025-final.pdf\">Revisoryttrande ABL 8-54 2025 final<\/a><\/h3>\n<h3><a href=\"https:\/\/www.egetis.com\/wp-content\/uploads\/SE-Egetis-Arsredovisning-2025-_-Final.pdf\">SE &#8211; Egetis &#8211; Arsredovisning 2025 _ Final<\/a><\/h3>\n","protected":false},"excerpt":{"rendered":"<p>\u00c5rsst\u00e4mman 2026 kommer att h\u00e5llas den 14 april 2026 i Stockholm. Kallelse Fullmaktsformul\u00e4r Anm\u00e4lan och formul\u00e4r f\u00f6r f\u00f6rhandsr\u00f6stning Valberedningens f\u00f6rslag och motiverade yttrande Board SHP 2026 Remuneration report_Final_2025_SE Revisoryttrande ABL 8-54 2025 final SE &#8211; Egetis &#8211; Arsredovisning 2025 _ Final<\/p>\n","protected":false},"author":5,"featured_media":0,"parent":229,"menu_order":4,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-9825","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>\u00c5rsst\u00e4mma 2026 - Egetis Therapeutics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.egetis.com\/sv\/bolagsstyrning\/bolagsstamma\/arsstamma-2026\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u00c5rsst\u00e4mma 2026 - Egetis Therapeutics\" \/>\n<meta property=\"og:description\" content=\"\u00c5rsst\u00e4mman 2026 kommer att h\u00e5llas den 14 april 2026 i Stockholm. Kallelse Fullmaktsformul\u00e4r Anm\u00e4lan och formul\u00e4r f\u00f6r f\u00f6rhandsr\u00f6stning Valberedningens f\u00f6rslag och motiverade yttrande Board SHP 2026 Remuneration report_Final_2025_SE Revisoryttrande ABL 8-54 2025 final SE &#8211; Egetis &#8211; Arsredovisning 2025 _ Final\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.egetis.com\/sv\/bolagsstyrning\/bolagsstamma\/arsstamma-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Egetis Therapeutics\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-24T12:49:07+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.egetis.com\/sv\/bolagsstyrning\/bolagsstamma\/arsstamma-2026\/\",\"url\":\"https:\/\/www.egetis.com\/sv\/bolagsstyrning\/bolagsstamma\/arsstamma-2026\/\",\"name\":\"\u00c5rsst\u00e4mma 2026 - Egetis Therapeutics\",\"isPartOf\":{\"@id\":\"https:\/\/www.egetis.com\/sv\/#website\"},\"datePublished\":\"2026-01-29T18:29:19+00:00\",\"dateModified\":\"2026-03-24T12:49:07+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.egetis.com\/sv\/bolagsstyrning\/bolagsstamma\/arsstamma-2026\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.egetis.com\/sv\/bolagsstyrning\/bolagsstamma\/arsstamma-2026\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.egetis.com\/sv\/bolagsstyrning\/bolagsstamma\/arsstamma-2026\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\/\/www.egetis.com\/sv\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bolagsstyrning\",\"item\":\"https:\/\/www.egetis.com\/sv\/bolagsstyrning\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Bolagsst\u00e4mmor\",\"item\":\"https:\/\/www.egetis.com\/sv\/bolagsstyrning\/bolagsstamma\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"\u00c5rsst\u00e4mma 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.egetis.com\/sv\/#website\",\"url\":\"https:\/\/www.egetis.com\/sv\/\",\"name\":\"Egetis Therapeutics\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.egetis.com\/sv\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u00c5rsst\u00e4mma 2026 - Egetis Therapeutics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.egetis.com\/sv\/bolagsstyrning\/bolagsstamma\/arsstamma-2026\/","og_locale":"sv_SE","og_type":"article","og_title":"\u00c5rsst\u00e4mma 2026 - Egetis Therapeutics","og_description":"\u00c5rsst\u00e4mman 2026 kommer att h\u00e5llas den 14 april 2026 i Stockholm. Kallelse Fullmaktsformul\u00e4r Anm\u00e4lan och formul\u00e4r f\u00f6r f\u00f6rhandsr\u00f6stning Valberedningens f\u00f6rslag och motiverade yttrande Board SHP 2026 Remuneration report_Final_2025_SE Revisoryttrande ABL 8-54 2025 final SE &#8211; Egetis &#8211; Arsredovisning 2025 _ Final","og_url":"https:\/\/www.egetis.com\/sv\/bolagsstyrning\/bolagsstamma\/arsstamma-2026\/","og_site_name":"Egetis Therapeutics","article_modified_time":"2026-03-24T12:49:07+00:00","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.egetis.com\/sv\/bolagsstyrning\/bolagsstamma\/arsstamma-2026\/","url":"https:\/\/www.egetis.com\/sv\/bolagsstyrning\/bolagsstamma\/arsstamma-2026\/","name":"\u00c5rsst\u00e4mma 2026 - Egetis Therapeutics","isPartOf":{"@id":"https:\/\/www.egetis.com\/sv\/#website"},"datePublished":"2026-01-29T18:29:19+00:00","dateModified":"2026-03-24T12:49:07+00:00","breadcrumb":{"@id":"https:\/\/www.egetis.com\/sv\/bolagsstyrning\/bolagsstamma\/arsstamma-2026\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.egetis.com\/sv\/bolagsstyrning\/bolagsstamma\/arsstamma-2026\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.egetis.com\/sv\/bolagsstyrning\/bolagsstamma\/arsstamma-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.egetis.com\/sv\/"},{"@type":"ListItem","position":2,"name":"Bolagsstyrning","item":"https:\/\/www.egetis.com\/sv\/bolagsstyrning\/"},{"@type":"ListItem","position":3,"name":"Bolagsst\u00e4mmor","item":"https:\/\/www.egetis.com\/sv\/bolagsstyrning\/bolagsstamma\/"},{"@type":"ListItem","position":4,"name":"\u00c5rsst\u00e4mma 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.egetis.com\/sv\/#website","url":"https:\/\/www.egetis.com\/sv\/","name":"Egetis Therapeutics","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.egetis.com\/sv\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"}]}},"_links":{"self":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/pages\/9825","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/comments?post=9825"}],"version-history":[{"count":0,"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/pages\/9825\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/pages\/229"}],"wp:attachment":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/media?parent=9825"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}},{"id":9551,"date":"2024-10-02T16:44:04","date_gmt":"2024-10-02T14:44:04","guid":{"rendered":"https:\/\/www.egetis.com\/?page_id=9551"},"modified":"2024-10-28T10:08:18","modified_gmt":"2024-10-28T09:08:18","slug":"riktad-emission-2024","status":"publish","type":"page","link":"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/riktad-emission-2024\/","title":{"rendered":"Riktad emission 2024"},"content":{"rendered":"<p><strong><a href=\"https:\/\/www.egetis.com\/wp-content\/uploads\/Egetis-Therapeutics-AB-publ-Prospekt.pdf\">Egetis Therapeutics AB (publ) &#8211; Prospekt<\/a><\/strong><\/p>\n<p><a href=\"https:\/\/www.egetis.com\/sv\/bolagsstyrning\/bolagsstamma\/extra-bolagsstamma-25-oktober-2024\/\">L\u00e4nk till formul\u00e4r f\u00f6r den extra bolagsst\u00e4mman 25 oktober 2024<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Egetis Therapeutics AB (publ) &#8211; Prospekt L\u00e4nk till formul\u00e4r f\u00f6r den extra bolagsst\u00e4mman 25 oktober 2024<\/p>\n","protected":false},"author":5,"featured_media":0,"parent":5170,"menu_order":12,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-9551","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Riktad emission 2024 - Egetis Therapeutics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/riktad-emission-2024\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Riktad emission 2024 - Egetis Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Egetis Therapeutics AB (publ) &#8211; Prospekt L\u00e4nk till formul\u00e4r f\u00f6r den extra bolagsst\u00e4mman 25 oktober 2024\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/riktad-emission-2024\/\" \/>\n<meta property=\"og:site_name\" content=\"Egetis Therapeutics\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-28T09:08:18+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/riktad-emission-2024\/\",\"url\":\"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/riktad-emission-2024\/\",\"name\":\"Riktad emission 2024 - Egetis Therapeutics\",\"isPartOf\":{\"@id\":\"https:\/\/www.egetis.com\/sv\/#website\"},\"datePublished\":\"2024-10-02T14:44:04+00:00\",\"dateModified\":\"2024-10-28T09:08:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/riktad-emission-2024\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/riktad-emission-2024\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/riktad-emission-2024\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\/\/www.egetis.com\/sv\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Investerare\",\"item\":\"https:\/\/www.egetis.com\/sv\/investerare\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nyemissioner\",\"item\":\"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Riktad emission 2024\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.egetis.com\/sv\/#website\",\"url\":\"https:\/\/www.egetis.com\/sv\/\",\"name\":\"Egetis Therapeutics\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.egetis.com\/sv\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Riktad emission 2024 - Egetis Therapeutics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/riktad-emission-2024\/","og_locale":"sv_SE","og_type":"article","og_title":"Riktad emission 2024 - Egetis Therapeutics","og_description":"Egetis Therapeutics AB (publ) &#8211; Prospekt L\u00e4nk till formul\u00e4r f\u00f6r den extra bolagsst\u00e4mman 25 oktober 2024","og_url":"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/riktad-emission-2024\/","og_site_name":"Egetis Therapeutics","article_modified_time":"2024-10-28T09:08:18+00:00","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/riktad-emission-2024\/","url":"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/riktad-emission-2024\/","name":"Riktad emission 2024 - Egetis Therapeutics","isPartOf":{"@id":"https:\/\/www.egetis.com\/sv\/#website"},"datePublished":"2024-10-02T14:44:04+00:00","dateModified":"2024-10-28T09:08:18+00:00","breadcrumb":{"@id":"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/riktad-emission-2024\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/riktad-emission-2024\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/riktad-emission-2024\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.egetis.com\/sv\/"},{"@type":"ListItem","position":2,"name":"Investerare","item":"https:\/\/www.egetis.com\/sv\/investerare\/"},{"@type":"ListItem","position":3,"name":"Nyemissioner","item":"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/"},{"@type":"ListItem","position":4,"name":"Riktad emission 2024"}]},{"@type":"WebSite","@id":"https:\/\/www.egetis.com\/sv\/#website","url":"https:\/\/www.egetis.com\/sv\/","name":"Egetis Therapeutics","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.egetis.com\/sv\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"}]}},"_links":{"self":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/pages\/9551","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/comments?post=9551"}],"version-history":[{"count":0,"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/pages\/9551\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/pages\/5170"}],"wp:attachment":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/media?parent=9551"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}},{"id":9514,"date":"2024-10-01T13:07:41","date_gmt":"2024-10-01T11:07:41","guid":{"rendered":"https:\/\/www.egetis.com\/?page_id=9514"},"modified":"2025-01-28T12:59:25","modified_gmt":"2025-01-28T11:59:25","slug":"extra-bolagsstamma-25-oktober-2024","status":"publish","type":"page","link":"https:\/\/www.egetis.com\/sv\/bolagsstyrning\/bolagsstamma\/extra-bolagsstamma-25-oktober-2024\/","title":{"rendered":"Extra bolagsst\u00e4mma 25 oktober 2024"},"content":{"rendered":"<p><a href=\"https:\/\/www.egetis.com\/wp-content\/uploads\/Egetis-EGM-2024-Kallelse-Sv.pdf\"><strong>Egetis &#8211; EGM 2024 &#8211; Kallelse (Sv)<\/strong><\/a><\/p>\n<p><strong><a href=\"https:\/\/www.egetis.com\/wp-content\/uploads\/Egetis-EGM-2024-Anmalan-och-formular-for-forhandsrostning-Sv.pdf\">Egetis &#8211; EGM 2024 &#8211; Anm\u00e4lan och formul\u00e4r f\u00f6r f\u00f6rhandsr\u00f6stning (Sv)<\/a><\/strong><\/p>\n<p><strong><a href=\"https:\/\/www.egetis.com\/wp-content\/uploads\/Egetis-EGM-2024-Fullmaktsformular-Sv.pdf\">Egetis &#8211; EGM 2024 &#8211; Fullmaktsformul\u00e4r (Sv)<\/a><\/strong><\/p>\n<p><strong><a href=\"https:\/\/www.egetis.com\/wp-content\/uploads\/Egetis-EGM-2024-Revisorsyttrande-enligt-13-kap-6-\u00a7-ABL-Sv.pdf\">Egetis &#8211; EGM 2024 &#8211; Revisorsyttrande enligt 13 kap 6 \u00a7 ABL (Sv)<\/a><\/strong><\/p>\n<p><strong><a href=\"https:\/\/www.egetis.com\/wp-content\/uploads\/Egetis-EGM-2024-Styrelsens-redogorelse-enligt-13-kap-6-\u00a7-ABL-Sv-Eng.pdf\">Egetis &#8211; EGM 2024 &#8211; Styrelsens redog\u00f6relse enligt 13 kap 6 \u00a7 ABL (Sv &amp; Eng)<\/a> <\/strong><\/p>\n<p><strong><a href=\"https:\/\/www.egetis.com\/wp-content\/uploads\/Egetis-EGM-2024-Stammoprotokoll-hemsida.pdf\">Egetis &#8211; EGM 2024 &#8211; St\u00e4mmoprotokoll hemsida<\/a><\/strong><\/p>\n<p><strong><a href=\"https:\/\/www.egetis.com\/wp-content\/uploads\/Egetis-Therapeutics-AB-publ-Registreringsbevis.pdf\">Egetis Therapeutics AB (publ) &#8211; Registreringsbevis<\/a><\/strong><\/p>\n<p><strong><a href=\"https:\/\/www.egetis.com\/wp-content\/uploads\/Egetis-Therapeutics-AB-publ-Prospekt.pdf\">Egetis Therapeutics AB (publ) &#8211; Prospekt<\/a><\/strong><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Egetis &#8211; EGM 2024 &#8211; Kallelse (Sv) Egetis &#8211; EGM 2024 &#8211; Anm\u00e4lan och formul\u00e4r f\u00f6r f\u00f6rhandsr\u00f6stning (Sv) Egetis &#8211; EGM 2024 &#8211; Fullmaktsformul\u00e4r (Sv) Egetis &#8211; EGM 2024 &#8211; Revisorsyttrande enligt 13 kap 6 \u00a7 ABL (Sv) Egetis &#8211; EGM 2024 &#8211; Styrelsens redog\u00f6relse enligt 13 kap 6 \u00a7 ABL (Sv &amp; Eng) Egetis [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":0,"parent":229,"menu_order":8,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-9514","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Extra bolagsst\u00e4mma 25 oktober 2024 - Egetis Therapeutics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.egetis.com\/sv\/bolagsstyrning\/bolagsstamma\/extra-bolagsstamma-25-oktober-2024\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Extra bolagsst\u00e4mma 25 oktober 2024 - Egetis Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Egetis &#8211; EGM 2024 &#8211; Kallelse (Sv) Egetis &#8211; EGM 2024 &#8211; Anm\u00e4lan och formul\u00e4r f\u00f6r f\u00f6rhandsr\u00f6stning (Sv) Egetis &#8211; EGM 2024 &#8211; Fullmaktsformul\u00e4r (Sv) Egetis &#8211; EGM 2024 &#8211; Revisorsyttrande enligt 13 kap 6 \u00a7 ABL (Sv) Egetis &#8211; EGM 2024 &#8211; Styrelsens redog\u00f6relse enligt 13 kap 6 \u00a7 ABL (Sv &amp; Eng) Egetis [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.egetis.com\/sv\/bolagsstyrning\/bolagsstamma\/extra-bolagsstamma-25-oktober-2024\/\" \/>\n<meta property=\"og:site_name\" content=\"Egetis Therapeutics\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-28T11:59:25+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.egetis.com\/sv\/bolagsstyrning\/bolagsstamma\/extra-bolagsstamma-25-oktober-2024\/\",\"url\":\"https:\/\/www.egetis.com\/sv\/bolagsstyrning\/bolagsstamma\/extra-bolagsstamma-25-oktober-2024\/\",\"name\":\"Extra bolagsst\u00e4mma 25 oktober 2024 - Egetis Therapeutics\",\"isPartOf\":{\"@id\":\"https:\/\/www.egetis.com\/sv\/#website\"},\"datePublished\":\"2024-10-01T11:07:41+00:00\",\"dateModified\":\"2025-01-28T11:59:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.egetis.com\/sv\/bolagsstyrning\/bolagsstamma\/extra-bolagsstamma-25-oktober-2024\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.egetis.com\/sv\/bolagsstyrning\/bolagsstamma\/extra-bolagsstamma-25-oktober-2024\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.egetis.com\/sv\/bolagsstyrning\/bolagsstamma\/extra-bolagsstamma-25-oktober-2024\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\/\/www.egetis.com\/sv\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bolagsstyrning\",\"item\":\"https:\/\/www.egetis.com\/sv\/bolagsstyrning\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Bolagsst\u00e4mmor\",\"item\":\"https:\/\/www.egetis.com\/sv\/bolagsstyrning\/bolagsstamma\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Extra bolagsst\u00e4mma 25 oktober 2024\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.egetis.com\/sv\/#website\",\"url\":\"https:\/\/www.egetis.com\/sv\/\",\"name\":\"Egetis Therapeutics\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.egetis.com\/sv\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Extra bolagsst\u00e4mma 25 oktober 2024 - Egetis Therapeutics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.egetis.com\/sv\/bolagsstyrning\/bolagsstamma\/extra-bolagsstamma-25-oktober-2024\/","og_locale":"sv_SE","og_type":"article","og_title":"Extra bolagsst\u00e4mma 25 oktober 2024 - Egetis Therapeutics","og_description":"Egetis &#8211; EGM 2024 &#8211; Kallelse (Sv) Egetis &#8211; EGM 2024 &#8211; Anm\u00e4lan och formul\u00e4r f\u00f6r f\u00f6rhandsr\u00f6stning (Sv) Egetis &#8211; EGM 2024 &#8211; Fullmaktsformul\u00e4r (Sv) Egetis &#8211; EGM 2024 &#8211; Revisorsyttrande enligt 13 kap 6 \u00a7 ABL (Sv) Egetis &#8211; EGM 2024 &#8211; Styrelsens redog\u00f6relse enligt 13 kap 6 \u00a7 ABL (Sv &amp; Eng) Egetis [&hellip;]","og_url":"https:\/\/www.egetis.com\/sv\/bolagsstyrning\/bolagsstamma\/extra-bolagsstamma-25-oktober-2024\/","og_site_name":"Egetis Therapeutics","article_modified_time":"2025-01-28T11:59:25+00:00","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.egetis.com\/sv\/bolagsstyrning\/bolagsstamma\/extra-bolagsstamma-25-oktober-2024\/","url":"https:\/\/www.egetis.com\/sv\/bolagsstyrning\/bolagsstamma\/extra-bolagsstamma-25-oktober-2024\/","name":"Extra bolagsst\u00e4mma 25 oktober 2024 - Egetis Therapeutics","isPartOf":{"@id":"https:\/\/www.egetis.com\/sv\/#website"},"datePublished":"2024-10-01T11:07:41+00:00","dateModified":"2025-01-28T11:59:25+00:00","breadcrumb":{"@id":"https:\/\/www.egetis.com\/sv\/bolagsstyrning\/bolagsstamma\/extra-bolagsstamma-25-oktober-2024\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.egetis.com\/sv\/bolagsstyrning\/bolagsstamma\/extra-bolagsstamma-25-oktober-2024\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.egetis.com\/sv\/bolagsstyrning\/bolagsstamma\/extra-bolagsstamma-25-oktober-2024\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.egetis.com\/sv\/"},{"@type":"ListItem","position":2,"name":"Bolagsstyrning","item":"https:\/\/www.egetis.com\/sv\/bolagsstyrning\/"},{"@type":"ListItem","position":3,"name":"Bolagsst\u00e4mmor","item":"https:\/\/www.egetis.com\/sv\/bolagsstyrning\/bolagsstamma\/"},{"@type":"ListItem","position":4,"name":"Extra bolagsst\u00e4mma 25 oktober 2024"}]},{"@type":"WebSite","@id":"https:\/\/www.egetis.com\/sv\/#website","url":"https:\/\/www.egetis.com\/sv\/","name":"Egetis Therapeutics","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.egetis.com\/sv\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"}]}},"_links":{"self":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/pages\/9514","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/comments?post=9514"}],"version-history":[{"count":0,"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/pages\/9514\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/pages\/229"}],"wp:attachment":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/media?parent=9514"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}},{"id":9411,"date":"2024-05-07T14:21:50","date_gmt":"2024-05-07T12:21:50","guid":{"rendered":"https:\/\/www.egetis.com\/?page_id=9411"},"modified":"2026-02-05T09:45:58","modified_gmt":"2026-02-05T08:45:58","slug":"privacy-notice","status":"publish","type":"page","link":"https:\/\/www.egetis.com\/sv\/privacy-notice\/","title":{"rendered":"Privacy Notice"},"content":{"rendered":"<h2>1 GENERAL<\/h2>\n<p>1.1 This Privacy Notice (\u201c<strong>Privacy Notice<\/strong>\u201d), describes how Egetis Therapeutics AB (publ), registration number 556706-6724, Klara Norra Kyrkogata 26, SE-111 22 Stockholm, Sweden and its affiliates (collectively \u201c<strong>Egetis<\/strong>\u201d), collects, uses, discloses, stores, transfers, share and otherwise process personal data.<\/p>\n<p>1.2 We respect your right to privacy and are committed to complying with applicable data protection rules and to safeguarding your rights. We want to make sure that you are aware of what types of information we collect or obtain from you via our websites or during your communication or interaction with us, how this information is used and how we work to protect it.<\/p>\n<p>1.3 This Privacy Notice describes, amongst other things, which information we collect about you and any of your employees, officers, directors, agents, contractors or consultants or any of your customers, suppliers or any other relevant individual, how such personal data is processed and for what purposes we collect and use the personal data. This Privacy Notice also describes your rights and how you can contact us about the use of your personal data.<\/p>\n<p>1.4 Egetis is the data controller responsible for processing your Personal Data (as defined below) in accordance with applicable data protection legislation.<\/p>\n<h2>WHAT TYPES OF DATA DO WE PROCESS?<\/h2>\n<p>2.1 \u201c<strong>Personal Data<\/strong>\u201d means all any information relating to an identified or identifiable natural person (\u201c<strong>Data Subject<\/strong>\u201d); an identifiable natural person is one who can be identified, directly or indirectly, in particular by reference to an identifier such as a name, an identification number, location data, an online identifier or to one or more factors specific to the physical, physiological, genetic, mental, economic, cultural or social identity of that natural person.<\/p>\n<p>2.2 How do we collect your personal data? We collect personal data that you provide to us in the following ways:<\/p>\n<div class=\"con-div\">\n<p class=\"letter-indent\">2.2.1 Entering into agreement with Egetis: when you enter into a contractual agreement with us, we may collect certain details in respect of you or other representatives of your business.<\/p>\n<p class=\"letter-indent\">2.2.2 Communications with us directly: we collect Personal Data you submit, provide or post to us directly, such as via postal, telephone and\/or email communications.<\/p>\n<p class=\"letter-indent\">2.2.3 When you have agreed to receiving communications from us, we will collect and process your contact information and other identifiers including your e-mail address, phone number and name.<\/p>\n<p class=\"letter-indent\">2.2.4 Communications via our website: we collect Personal Data when you provide it to us through communications via our website. This includes where you have contacted us through the \u201cContact\u201d page on our website.<\/p>\n<p class=\"letter-indent\">2.2.5 Events: when we arrange or attend events, we may collect your Personal Data when you attend the event and exchange your details with us (for example, by providing your business card).<\/p>\n<\/div>\n<p>2.3 Egetis further collects and processes your business contact information and other identifiers that are necessary for us to contact you in your role as a representative for a company if you represent a company that is a customer, supplier, contractor or otherwise partner of ours, as well as a potential customer, supplier, contractor or otherwise partner of ours. The information that we collect and process in such cases includes business contact information (such as name, address, work title, what company you work for, email address, telephone number, bank details).<\/p>\n<p>2.4 Egetis also collects Personal Data used for the purpose of recruiting members of staff. When you contact us to apply for a job opportunity with us, we collect such Personal Data that you provide us with in connection with such application. Personal Data normally included in a job application is contact information (name, address, email address and telephone number), CV (including previous work experience and education), and occasionally picture and personal registration number.<\/p>\n<p>2.5 Egetis collects and processes your device, Internet and network activity information when you use our websites. We may process information about your browser, device, the operating system you are using, your device identifiers, MAC address, and IP address, as well as information at the site you came from, the site you visit when you leave us, and your page interactions that we collect through cookies and similar technologies upon your consent, or if they are strictly necessary for operating our website, based on our legitimate interest. For more information regarding cookies and similar tracking technologies, please visit our <a href=\"https:\/\/www.egetis.com\/sv\/cookie-policy\/\" target=\"_blank\" rel=\"noopener\">cookie policy<\/a>.<br \/>\nIf you want to change the cookies you consented to, please open the website\u2019s cookie settings.<\/p>\n<p>2.6 If you are a healthcare practitioner and consent to that, Egetis collects and processes your contact information and other identifiers including your name, title, e-mail address, medical specialization, and address of your medical practice to enroll you into our disease awareness program and be provided with resources to diagnose and manage people living with MCT8 deficiency.<\/p>\n<p>2.7 We generally do not collect special category Personal Data through our website, such as gender, health or political opinions. If we are to collect Personal Data of a special category, we will provide you with information about that processing before the data is collected.<\/p>\n<p>2.8 If your treating physician or healthcare practitioner determines that you are eligible to participate in an Egetis Managed Access Program (&#8221;<strong>Managed Access<\/strong>&#8221;), your physician may share limited Personal Data with us to facilitate the supply of the relevant product. In rare cases, such as when we are required to distribute the product directly to you, we may collect and process limited identifiable Personal Data, such as your name and address, solely for the purpose of ensuring delivery of the product. For more information about Managed Access, please see our Managed Access Policy <a href=\"https:\/\/www.egetis.com\/sv\/pipeline\/managed-access-policy\/\" target=\"_blank\" rel=\"noopener\">here<\/a>.<\/p>\n<p>2.9 If you are a patient in one of our clinical studies or Managed Access, we may process your Personal Data for pharmacovigilance purposes. This means we may process your Personal Data to monitor the safety of the medicine you have received. This includes collecting and assessing information related to any adverse events or product quality issues.<\/p>\n<h2>3 WHY DO WE PROCESS YOUR DATA?<\/h2>\n<p>3.1 We process Personal Data where we have a legal basis to do so. The legal basis depends on the purposes and reasons why we process your data:<\/p>\n<div class=\"con-div\">\n<p class=\"letter-indent\">a) Processing is necessary for the legitimate interests pursued by us or by a third party \u2013 the legal basis we rely on to process your Personal Data in this specific situation is Article 6(1)(f) of the Regulation (EU) 2016\/679 (General Data Protection Regulation or \u201c<strong>GDPR<\/strong>\u201d). We balance our legitimate interests or the interests of third parties against your rights and interests. This legal basis is relied on when we:<\/p>\n<p class=\"more-indent\">Send communications that you have requested and respond to communications you have sent us \u2013 our legitimate interest is marketing ourselves and our services.<\/p>\n<p class=\"more-indent\">Contact you as a representative for a customer, supplier, contractor or otherwise partner of ours \u2013 our legitimate interest is to administer the relationship we have with the company that you represent. We may reach out to you in situations where you provide us with your contact information by handing us a business card or otherwise have expressed an interest in our products or services.<\/p>\n<p class=\"more-indent\">Invite you to events we believe might be of interest to you or the company that you represent (provided however, that you will always have the right to opt-out of any marketing messages from us) \u2013 our legitimate interest is marketing our products and services.<\/p>\n<p class=\"more-indent\">Develop and improve our services, which is also our legitimate interest.<\/p>\n<p class=\"more-indent\">Respond to an enquiry or other request you make when you contact us via our website or directly \u2013 our legitimate interest is our business efficiency and marketing of our products and services.<\/p>\n<p class=\"more-indent\">Protect the security of and manage access to our premises, IT and communication systems, online platforms, website and other systems, preventing and detecting security threats, fraud or other criminal or malicious activities \u2013 our legitimate interest is our business continuity and security.<\/p>\n<p class=\"more-indent\">Notify you about changes to our service \u2013 our legitimate interest is our business efficiency.<\/p>\n<p class=\"more-indent\">Provide you with resources to diagnose and manage people living with MCT8 deficiency\u2013 our legitimate interest is to increase awareness about that rare disease.<\/p>\n<p class=\"letter-indent\">b) Processing is necessary for the performance of a contract to which you are a party or to take steps at your request before entering into a contract; the legal basis we rely on to process your Personal Data in this specific situation is Article 6(1)(b) of the GDPR. This legal basis is relied on when we:<\/p>\n<\/div>\n<p class=\"more-indent\">Process your job applications;<\/p>\n<p class=\"more-indent\">Carry out our obligations arising from any contracts, including providing you with the information you request from us.<\/p>\n<div class=\"con-div\">\n<p class=\"letter-indent\">c) We process Personal Data where we need to comply with a legal obligation, such as the Swedish Accounting Act. The legal basis we rely on to process your personal data in this specific situation is Article 6(1)(c) of the GDPR. We may also process Personal Data where it is necessary to carry out statistical and other analyses and to meet our legal or regulatory obligations.<\/p>\n<\/div>\n<div class=\"con-div\">\n<p class=\"letter-indent\">d) For Managed Access, we rely on our legitimate interests and\/or the need to fulfil our obligations under the Managed Access arrangements as the legal basis for this data processing.<\/p>\n<\/div>\n<div class=\"con-div\">\n<p class=\"letter-indent\">e) Where we process your Personal Data for pharmacovigilance purposes, we do so to ensure patient safety and to comply with our obligations under applicable laws and regulations.<\/p>\n<\/div>\n<p>3.2 <strong>Direct Marketing<\/strong>: We reach out with our electronic message advertising or marketing materials directed to you as a natural person only if you consent to it, or we can rely on the so-called \u2018soft opt-in\u2019 exception, which means that your consent, as our existing customer, is implied. Any marketing communication will include a clear way for you to opt out of such communication.<\/p>\n<h2>4 FOR HOW LONG DO WE STORE YOUR PERSONAL DATA?<\/h2>\n<p>4.1 Your Personal Data is stored only for as long as there is a need to keep the data in order to fulfil the purposes for which the data was collected in accordance with this Privacy Notice.<\/p>\n<p>4.2 The Personal Data will be deleted if the purpose of collection and use of Personal Data has been achieved, or if you withdraw your consent (if applicable) to the processing of Personal Data by contacting us (for contact information, please see Section 9 below).<\/p>\n<p>4.3 Personal Data received in connection with a job application for an applicant who is not hired will be stored for no longer than one year after the date of the completion of the recruitment process.<\/p>\n<h2>5 HOW MAY THE DATA BE SHARED?<\/h2>\n<p>5.1 Egetis may share Personal Data with our trusted subcontractors and cooperation partners, including digital service providers, within the scope listed above. They may need access to your Personal Data in their assignment for us, but they will not be allowed to use the Personal Data for any other purpose, only according to our instructions.<\/p>\n<p>5.2 The personal data we collect may be transferred to and stored in countries outside of the jurisdiction you are in. When we transfer your Personal Data to any country outside the European Economic Area (\u201c<strong>EEA<\/strong>\u201d) and the UK, such transfers are made pursuant to appropriate safeguards.<\/p>\n<p>5.3 Personal Data that Egetis collects may be transferred to our trusted subcontractors based outside of EEA and the UK, including countries that do not provide the same level of protection for personal data as in the EEA, as a part of provision of services to Egetis.<\/p>\n<p>In any event, we will only transfer personal data to recipients that provide an adequate level of data protection or as permitted by applicable data protection laws by implementing appropriate safeguards, including, but not limited to, relevant data transfer agreements with standard contractual clauses approved by the European Commission (\u201c<strong>Model Clauses<\/strong>\u201d) to impose on the Personal Data recipient data protection and security obligations that are equivalent to the EEA standards.<\/p>\n<p>We transfer personal information to countries that are covered by adequacy decisions or subject to an equivalent framework.<\/p>\n<p>Personal Data will be transferred to the USA as we use service providers such as Office 365 (Microsoft Corporation) and Google Analytics (Google LLC). Egetis has ensured that your rights are guaranteed before making such a transfer to the USA by Microsoft\u2019s and Google\u2019s adherence to the EU-US Data Privacy Framework. To learn more about the Data Privacy Framework program, and to view our service providers\u2019 certifications, please visit <a href=\"https:\/\/www.dataprivacyframework.gov\/\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.dataprivacyframework.gov\/<\/a>.<\/p>\n<p>5.4 Personal Data may be disclosed by Egetis to comply with legal requirements or other requirements from official authorities, in order to safeguard Egetis legal interests or to detect, prevent, or draw attention to frauds or other safety or technical problems.<\/p>\n<h2>6 PROTECTION OF YOUR PERSONAL DATA<\/h2>\n<p>6.1. We have employed a wide range of security measures to help protect your Personal Data against accidental or unlawful destruction, loss, alteration, unauthorised disclosure of, or access to.<\/p>\n<p>6.2 We protect your Personal Data using commercially reasonable safeguards to prevent loss, misuse, unauthorized access, disclosure, alteration, and destruction. These measures include data encryption, firewalls, automatic timeouts and one-time access links that expire within hours. Therefore, you can rest assured that your Personal Data is in safe hands.<\/p>\n<h2>7 YOUR RIGHTS<\/h2>\n<p><em>In accordance with the <\/em>General Data Protection Regulation<em>, you have a right to:<\/em><\/p>\n<p>7.1 <em>Access:<\/em> You have the right to obtain confirmation whether we process Personal Data about you, as well as to request a copy of the Personal Data that Egetis processes about you. However, there are exceptions to this right, so that access may be limited if, for example, making the information available to you would adversely affect the rights and freedoms of another person, or if Egetis is legally prevented from disclosing such information. If you want a copy of the data related to you that Egetis processes, please contact us in accordance with the contact information found below.<\/p>\n<p>7.2 <em>Information<\/em>: You are entitled to access the following information about the processing that concerns you:<\/p>\n<p class=\"more-indent\">the purposes of the processing;<\/p>\n<p class=\"more-indent\">the categories of personal data concerned;<\/p>\n<p class=\"more-indent\">the recipients or categories of recipients to whom the personal data have been or will be disclosed, in particular recipients in third countries or international organisations;<\/p>\n<p class=\"more-indent\">where possible, the envisaged period for which the personal data will be stored, or, if not possible, the criteria used to determine that period;<\/p>\n<p class=\"more-indent\">the existence of the right to request from the controller rectification or erasure of personal data or restriction of processing of personal data concerning the data subject or to object to such processing;<\/p>\n<p class=\"more-indent\">the right to lodge a complaint with a supervisory authority;<\/p>\n<p class=\"more-indent\">where the personal data are not collected from the data subject, any available information as to their source;<\/p>\n<p class=\"more-indent\">the existence of automated decision-making, including profiling;<\/p>\n<p class=\"more-indent\">the appropriate safeguards for data transfers.<\/p>\n<p>7.3 <em>Accuracy:<\/em> Egetis aims to keep your personal data accurate, current, and complete. We encourage you to let us know by contacting us if any of your personal data is not accurate or has changed since you provided us with it.<\/p>\n<p>7.4 <em>Erasure<\/em>: You have the right to erase your personal data when the personal data is no longer necessary for the purposes for which it was collected, or when, among other things, your personal data have been unlawfully processed.<\/p>\n<p>7.5 <em>Restrict the processing<\/em>: Under certain circumstances (expressed in applicable data protection legislation), you may request that Egetis restricts the use of your Personal Data.<\/p>\n<p>7.6 <em>Objecting<\/em>: In certain circumstances, you have the right to object to processing of your personal data and to ask us to block, erase. If you would like us to stop using your personal data, please contact us in accordance with the contact information found below.<\/p>\n<p>7.7 <em>Data Portability<\/em>: In certain circumstances, you have the right to request that some of your personal data is provided to you, or to another data controller, in a commonly used, machine-readable format.<\/p>\n<p>7.8. <em>Complaint<\/em>: Should you be dissatisfied with our processing of your Personal Data, please let us know, and we will do our best to address your complaints. The integrity of your Personal Data is very important to us, and we always strive to protect and secure your Personal Data in the best possible way. Should we nevertheless, in your opinion, fail in this ambition, please note that you are also entitled to lodge a complaint with the Swedish Authority for Privacy Protection (IMY).<\/p>\n<p><em>7.9 Revoke your consent: If the legal basis for processing is your consent, you have the right to withdraw consent at any time by emailing us using the contact details listed under Section 9.<\/em><\/p>\n<p>7.10 If you wish to exercise any of the abovementioned rights or if you have any questions regarding Personal Data held by us or this online Privacy Notice, please do not hesitate to contact us (for contact information, please see section 9 below).<\/p>\n<p>7.11 You are not required to pay any charge for exercising your rights, unless your request is unfounded, repetitive or excessive. If your request is unfounded, repetitive or excessive, or if we are not in a position to identify you, we can refuse to act on your request, or charge a reasonable fee.<\/p>\n<h2>8 CHANGES TO THIS PRIVACY NOTICE<\/h2>\n<p>Egetis may, at any time, make amendments to this Privacy Notice. Egetis will publish the amended version at our website. We encourage you to check this Privacy Notice for changes whenever you visit our website.<\/p>\n<h2>9 HOW TO CONTACT US<\/h2>\n<p>You can contact us at: Egetis Therapeutics AB (publ), Klara Norra Kyrkogata 26, SE-111 22 Stockholm, Sweden or at <a href=\"mailto:privacy@egetis.com\">privacy@egetis.com<\/a>.<\/p>\n<p>Rare Thyroid Therapeutics International AB is a fully-owned subsidiary of Egetis.<\/p>\n<p>You can also contact Egetis\u2019 Data Protection Officer, MAQS Advokatbyr\u00e5 AB, Stureplan 19, 111 42 Stockholm, Sweden at <a href=\"mailto:EgetisDPO@maqs.com\">EgetisDPO@maqs.com<\/a>.<\/p>\n<p>&nbsp;<\/p>\n<h2><strong>SUPPLEMENTARY U.S. PRIVACY NOTICE<\/strong><\/h2>\n<p>This supplementary U.S. Privacy Notice is intended for U.S. residents and complements the Privacy Notice above. In the event of any conflict between the above Privacy Notice and what is stated below, the Supplementary U.S. Privacy Notice shall prevail in relation to U.S. residents, provided that applicable U.S. data protection legislation is in effect.<\/p>\n<h2><strong>10 CHILDREN\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/strong><\/h2>\n<p>The website is not intended for use by anyone under 18 years of age. If you are a parent or guardian of a child from whom you believe we have collected personal information in a manner prohibited by law, please contact us. If we learn that we have collected personal information through the website from a child without the consent of the child\u2019s parent or guardian as required by law, we will comply with applicable legal requirements to delete the information.<\/p>\n<h2><strong>11 NON-DISCRIMINATION<\/strong><\/h2>\n<p>Egetis will not discriminate against you for exercising your data subject rights, although some of the functionality and features available on services may change or no longer be available to you.<\/p>\n<h2>12 SALE AND SHARING OF PERSONAL INFORMATION<\/h2>\n<p>12.1 &#8221;Sale&#8221; means selling, renting, releasing, disclosing, disseminating, making available, transferring, or otherwise communicating personal information to a third party for monetary or other valuable consideration. In the preceding 12 months, we have not sold any categories of personal information to third parties.<\/p>\n<p>12.2 &#8221;Sharing&#8221; means disclosing personal information to a third party for cross-context behavioral advertising, whether or not for monetary or other valuable consideration. In the preceding 12 months, we have not shared any categories of personal information for cross-context behavioral advertising.<\/p>\n<p>12.3 You have the right to opt out of the sale of your personal information and the sharing of your personal information for cross-context behavioral advertising.<\/p>\n<h2><strong>13 YOUR RIGHTS<\/strong><\/h2>\n<p>13.1 Depending on applicable U.S. federal and state privacy laws, you may have certain rights regarding your personal information. These rights may include the right to:<\/p>\n<ol>\n<li>request confirmation of whether we process personal information about you and access such personal information;<\/li>\n<li>request information about the categories of personal information collected, the purposes for which it is used, and the categories of third parties with whom it is shared;<\/li>\n<li>request correction of inaccurate or incomplete personal information;<\/li>\n<li>request deletion of personal information, subject to applicable legal exceptions;<\/li>\n<li>opt out of certain processing activities, including the sale or sharing of personal information or targeted advertising, where applicable; and<\/li>\n<li>limit or object to certain uses of sensitive personal information, where required by law.<\/li>\n<\/ol>\n<p>13.2 The exercise of these rights may be subject to verification of identity and other limitations permitted by applicable law. You may submit requests to exercise your rights using the contact information provided above. In some states, you may also designate an authorized agent to make a request on your behalf, provided that the agent can submit proof that they have been validly authorized to act on your behalf in accordance\u00a0with applicable legislation.<\/p>\n<p>13.3 Please note that, in accordance with applicable law, we are not obligated to provide or delete consumer information that is de-identified in response to a consumer request or to re-identify individual data to verify a consumer request.<\/p>\n<p>&nbsp;<\/p>\n<p><strong>Effective as of 12 May 2025<\/strong><\/p>\n<p><strong>Last Updated: 5 February 2026<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>1 GENERAL 1.1 This Privacy Notice (\u201cPrivacy Notice\u201d), describes how Egetis Therapeutics AB (publ), registration number 556706-6724, Klara Norra Kyrkogata 26, SE-111 22 Stockholm, Sweden and its affiliates (collectively \u201cEgetis\u201d), collects, uses, discloses, stores, transfers, share and otherwise process personal data. 1.2 We respect your right to privacy and are committed to complying with applicable [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":0,"parent":0,"menu_order":2,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-9411","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Privacy Notice - Egetis Therapeutics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.egetis.com\/sv\/privacy-notice\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Privacy Notice - Egetis Therapeutics\" \/>\n<meta property=\"og:description\" content=\"1 GENERAL 1.1 This Privacy Notice (\u201cPrivacy Notice\u201d), describes how Egetis Therapeutics AB (publ), registration number 556706-6724, Klara Norra Kyrkogata 26, SE-111 22 Stockholm, Sweden and its affiliates (collectively \u201cEgetis\u201d), collects, uses, discloses, stores, transfers, share and otherwise process personal data. 1.2 We respect your right to privacy and are committed to complying with applicable [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.egetis.com\/sv\/privacy-notice\/\" \/>\n<meta property=\"og:site_name\" content=\"Egetis Therapeutics\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-05T08:45:58+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"16 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.egetis.com\/sv\/privacy-notice\/\",\"url\":\"https:\/\/www.egetis.com\/sv\/privacy-notice\/\",\"name\":\"Privacy Notice - Egetis Therapeutics\",\"isPartOf\":{\"@id\":\"https:\/\/www.egetis.com\/sv\/#website\"},\"datePublished\":\"2024-05-07T12:21:50+00:00\",\"dateModified\":\"2026-02-05T08:45:58+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.egetis.com\/sv\/privacy-notice\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.egetis.com\/sv\/privacy-notice\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.egetis.com\/sv\/privacy-notice\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\/\/www.egetis.com\/sv\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Privacy Notice\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.egetis.com\/sv\/#website\",\"url\":\"https:\/\/www.egetis.com\/sv\/\",\"name\":\"Egetis Therapeutics\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.egetis.com\/sv\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Privacy Notice - Egetis Therapeutics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.egetis.com\/sv\/privacy-notice\/","og_locale":"sv_SE","og_type":"article","og_title":"Privacy Notice - Egetis Therapeutics","og_description":"1 GENERAL 1.1 This Privacy Notice (\u201cPrivacy Notice\u201d), describes how Egetis Therapeutics AB (publ), registration number 556706-6724, Klara Norra Kyrkogata 26, SE-111 22 Stockholm, Sweden and its affiliates (collectively \u201cEgetis\u201d), collects, uses, discloses, stores, transfers, share and otherwise process personal data. 1.2 We respect your right to privacy and are committed to complying with applicable [&hellip;]","og_url":"https:\/\/www.egetis.com\/sv\/privacy-notice\/","og_site_name":"Egetis Therapeutics","article_modified_time":"2026-02-05T08:45:58+00:00","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"16 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.egetis.com\/sv\/privacy-notice\/","url":"https:\/\/www.egetis.com\/sv\/privacy-notice\/","name":"Privacy Notice - Egetis Therapeutics","isPartOf":{"@id":"https:\/\/www.egetis.com\/sv\/#website"},"datePublished":"2024-05-07T12:21:50+00:00","dateModified":"2026-02-05T08:45:58+00:00","breadcrumb":{"@id":"https:\/\/www.egetis.com\/sv\/privacy-notice\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.egetis.com\/sv\/privacy-notice\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.egetis.com\/sv\/privacy-notice\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.egetis.com\/sv\/"},{"@type":"ListItem","position":2,"name":"Privacy Notice"}]},{"@type":"WebSite","@id":"https:\/\/www.egetis.com\/sv\/#website","url":"https:\/\/www.egetis.com\/sv\/","name":"Egetis Therapeutics","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.egetis.com\/sv\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"}]}},"_links":{"self":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/pages\/9411","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/comments?post=9411"}],"version-history":[{"count":0,"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/pages\/9411\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/media?parent=9411"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}},{"id":9134,"date":"2023-10-11T16:05:32","date_gmt":"2023-10-11T14:05:32","guid":{"rendered":"https:\/\/www.egetis.com\/?page_id=9134"},"modified":"2024-10-27T21:52:20","modified_gmt":"2024-10-27T20:52:20","slug":"emission-2023","status":"publish","type":"page","link":"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/emission-2023\/","title":{"rendered":"Emission oktober 2023"},"content":{"rendered":"<p><a href=\"https:\/\/www.egetis.com\/wp-content\/uploads\/Egetis-Therapeutics-AB-publ-Prospekt-last.pdf\">Egetis Therapeutics AB (publ) &#8211; Prospekt (l\u00e5st)<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Egetis Therapeutics AB (publ) &#8211; Prospekt (l\u00e5st)<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":5170,"menu_order":13,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-9134","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Emission oktober 2023 - Egetis Therapeutics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/emission-2023\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Emission oktober 2023 - Egetis Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Egetis Therapeutics AB (publ) &#8211; Prospekt (l\u00e5st)\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/emission-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Egetis Therapeutics\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-27T20:52:20+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/emission-2023\/\",\"url\":\"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/emission-2023\/\",\"name\":\"Emission oktober 2023 - Egetis Therapeutics\",\"isPartOf\":{\"@id\":\"https:\/\/www.egetis.com\/sv\/#website\"},\"datePublished\":\"2023-10-11T14:05:32+00:00\",\"dateModified\":\"2024-10-27T20:52:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/emission-2023\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/emission-2023\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/emission-2023\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\/\/www.egetis.com\/sv\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Investerare\",\"item\":\"https:\/\/www.egetis.com\/sv\/investerare\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nyemissioner\",\"item\":\"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Emission oktober 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.egetis.com\/sv\/#website\",\"url\":\"https:\/\/www.egetis.com\/sv\/\",\"name\":\"Egetis Therapeutics\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.egetis.com\/sv\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Emission oktober 2023 - Egetis Therapeutics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/emission-2023\/","og_locale":"sv_SE","og_type":"article","og_title":"Emission oktober 2023 - Egetis Therapeutics","og_description":"Egetis Therapeutics AB (publ) &#8211; Prospekt (l\u00e5st)","og_url":"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/emission-2023\/","og_site_name":"Egetis Therapeutics","article_modified_time":"2024-10-27T20:52:20+00:00","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/emission-2023\/","url":"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/emission-2023\/","name":"Emission oktober 2023 - Egetis Therapeutics","isPartOf":{"@id":"https:\/\/www.egetis.com\/sv\/#website"},"datePublished":"2023-10-11T14:05:32+00:00","dateModified":"2024-10-27T20:52:20+00:00","breadcrumb":{"@id":"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/emission-2023\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/emission-2023\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/emission-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.egetis.com\/sv\/"},{"@type":"ListItem","position":2,"name":"Investerare","item":"https:\/\/www.egetis.com\/sv\/investerare\/"},{"@type":"ListItem","position":3,"name":"Nyemissioner","item":"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/"},{"@type":"ListItem","position":4,"name":"Emission oktober 2023"}]},{"@type":"WebSite","@id":"https:\/\/www.egetis.com\/sv\/#website","url":"https:\/\/www.egetis.com\/sv\/","name":"Egetis Therapeutics","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.egetis.com\/sv\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"}]}},"_links":{"self":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/pages\/9134","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/comments?post=9134"}],"version-history":[{"count":0,"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/pages\/9134\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/pages\/5170"}],"wp:attachment":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/media?parent=9134"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}},{"id":8216,"date":"2023-01-24T09:36:36","date_gmt":"2023-01-24T08:36:36","guid":{"rendered":"https:\/\/www.egetis.com\/?page_id=8216"},"modified":"2023-10-05T15:40:44","modified_gmt":"2023-10-05T13:40:44","slug":"samtycker-inte","status":"publish","type":"page","link":"https:\/\/www.egetis.com\/sv\/samtycker-inte\/","title":{"rendered":"Samtycker inte"},"content":{"rendered":"<hr style=\"display: none;\" \/>\n<p>Informationen p\u00e5 denna del av webbplatsen \u00e4r inte avsedd f\u00f6r, och f\u00e5r inte, direkt eller indirekt, helt eller delvis, distribueras, publiceras eller spridas i eller till USA (innefattande dess territorier och provinser), varje stat i USA samt District of Columbia (\u201dUSA\u201d), Australien, Kanada, Hongkong, Israel, Japan, Nya Zeeland, Sydafrika, Schweiz eller n\u00e5gon annan jurisdiktion d\u00e4r s\u00e5dan \u00e5tg\u00e4rd kan utg\u00f6ra brott mot lokala v\u00e4rdepapperslagar eller best\u00e4mmelser i en s\u00e5dan jurisdiktion.<\/p>\n<p><a href=\"https:\/\/www.egetis.com\/sv\/\">\u00c5terg\u00e5 till hemsidan<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Informationen p\u00e5 denna del av webbplatsen \u00e4r inte avsedd f\u00f6r, och f\u00e5r inte, direkt eller indirekt, helt eller delvis, distribueras, publiceras eller spridas i eller till USA (innefattande dess territorier och provinser), varje stat i USA samt District of Columbia (\u201dUSA\u201d), Australien, Kanada, Hongkong, Israel, Japan, Nya Zeeland, Sydafrika, Schweiz eller n\u00e5gon annan jurisdiktion d\u00e4r [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":1000013,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-8216","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Samtycker inte - Egetis Therapeutics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.egetis.com\/sv\/samtycker-inte\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Samtycker inte - Egetis Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Informationen p\u00e5 denna del av webbplatsen \u00e4r inte avsedd f\u00f6r, och f\u00e5r inte, direkt eller indirekt, helt eller delvis, distribueras, publiceras eller spridas i eller till USA (innefattande dess territorier och provinser), varje stat i USA samt District of Columbia (\u201dUSA\u201d), Australien, Kanada, Hongkong, Israel, Japan, Nya Zeeland, Sydafrika, Schweiz eller n\u00e5gon annan jurisdiktion d\u00e4r [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.egetis.com\/sv\/samtycker-inte\/\" \/>\n<meta property=\"og:site_name\" content=\"Egetis Therapeutics\" \/>\n<meta property=\"article:modified_time\" content=\"2023-10-05T13:40:44+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.egetis.com\/sv\/samtycker-inte\/\",\"url\":\"https:\/\/www.egetis.com\/sv\/samtycker-inte\/\",\"name\":\"Samtycker inte - Egetis Therapeutics\",\"isPartOf\":{\"@id\":\"https:\/\/www.egetis.com\/sv\/#website\"},\"datePublished\":\"2023-01-24T08:36:36+00:00\",\"dateModified\":\"2023-10-05T13:40:44+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.egetis.com\/sv\/samtycker-inte\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.egetis.com\/sv\/samtycker-inte\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.egetis.com\/sv\/samtycker-inte\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\/\/www.egetis.com\/sv\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Samtycker inte\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.egetis.com\/sv\/#website\",\"url\":\"https:\/\/www.egetis.com\/sv\/\",\"name\":\"Egetis Therapeutics\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.egetis.com\/sv\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Samtycker inte - Egetis Therapeutics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.egetis.com\/sv\/samtycker-inte\/","og_locale":"sv_SE","og_type":"article","og_title":"Samtycker inte - Egetis Therapeutics","og_description":"Informationen p\u00e5 denna del av webbplatsen \u00e4r inte avsedd f\u00f6r, och f\u00e5r inte, direkt eller indirekt, helt eller delvis, distribueras, publiceras eller spridas i eller till USA (innefattande dess territorier och provinser), varje stat i USA samt District of Columbia (\u201dUSA\u201d), Australien, Kanada, Hongkong, Israel, Japan, Nya Zeeland, Sydafrika, Schweiz eller n\u00e5gon annan jurisdiktion d\u00e4r [&hellip;]","og_url":"https:\/\/www.egetis.com\/sv\/samtycker-inte\/","og_site_name":"Egetis Therapeutics","article_modified_time":"2023-10-05T13:40:44+00:00","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.egetis.com\/sv\/samtycker-inte\/","url":"https:\/\/www.egetis.com\/sv\/samtycker-inte\/","name":"Samtycker inte - Egetis Therapeutics","isPartOf":{"@id":"https:\/\/www.egetis.com\/sv\/#website"},"datePublished":"2023-01-24T08:36:36+00:00","dateModified":"2023-10-05T13:40:44+00:00","breadcrumb":{"@id":"https:\/\/www.egetis.com\/sv\/samtycker-inte\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.egetis.com\/sv\/samtycker-inte\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.egetis.com\/sv\/samtycker-inte\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.egetis.com\/sv\/"},{"@type":"ListItem","position":2,"name":"Samtycker inte"}]},{"@type":"WebSite","@id":"https:\/\/www.egetis.com\/sv\/#website","url":"https:\/\/www.egetis.com\/sv\/","name":"Egetis Therapeutics","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.egetis.com\/sv\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"}]}},"_links":{"self":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/pages\/8216","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/comments?post=8216"}],"version-history":[{"count":0,"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/pages\/8216\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/media?parent=8216"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}},{"id":7654,"date":"2022-03-22T16:50:50","date_gmt":"2022-03-22T15:50:50","guid":{"rendered":"https:\/\/www.egetis.com\/?page_id=7654"},"modified":"2022-04-28T14:14:34","modified_gmt":"2022-04-28T12:14:34","slug":"emission-2022","status":"publish","type":"page","link":"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/emission-2022\/","title":{"rendered":"Emission 2022"},"content":{"rendered":"<p><a href=\"https:\/\/www.egetis.com\/wp-content\/uploads\/Prospekt-last-Egetis-Therapeutics-AB-FINAL-2022-04-27.pdf\">Prospekt Egetis Therapeutics F\u00f6retr\u00e4desemission 2022<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Prospekt Egetis Therapeutics F\u00f6retr\u00e4desemission 2022<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":5170,"menu_order":28,"comment_status":"closed","ping_status":"closed","template":"modular-finance-moduler.php","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-7654","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Emission 2022 - Egetis Therapeutics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/emission-2022\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Emission 2022 - Egetis Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Prospekt Egetis Therapeutics F\u00f6retr\u00e4desemission 2022\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/emission-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Egetis Therapeutics\" \/>\n<meta property=\"article:modified_time\" content=\"2022-04-28T12:14:34+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/emission-2022\/\",\"url\":\"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/emission-2022\/\",\"name\":\"Emission 2022 - Egetis Therapeutics\",\"isPartOf\":{\"@id\":\"https:\/\/www.egetis.com\/sv\/#website\"},\"datePublished\":\"2022-03-22T15:50:50+00:00\",\"dateModified\":\"2022-04-28T12:14:34+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/emission-2022\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/emission-2022\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/emission-2022\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\/\/www.egetis.com\/sv\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Investerare\",\"item\":\"https:\/\/www.egetis.com\/sv\/investerare\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nyemissioner\",\"item\":\"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Emission 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.egetis.com\/sv\/#website\",\"url\":\"https:\/\/www.egetis.com\/sv\/\",\"name\":\"Egetis Therapeutics\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.egetis.com\/sv\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Emission 2022 - Egetis Therapeutics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/emission-2022\/","og_locale":"sv_SE","og_type":"article","og_title":"Emission 2022 - Egetis Therapeutics","og_description":"Prospekt Egetis Therapeutics F\u00f6retr\u00e4desemission 2022","og_url":"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/emission-2022\/","og_site_name":"Egetis Therapeutics","article_modified_time":"2022-04-28T12:14:34+00:00","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/emission-2022\/","url":"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/emission-2022\/","name":"Emission 2022 - Egetis Therapeutics","isPartOf":{"@id":"https:\/\/www.egetis.com\/sv\/#website"},"datePublished":"2022-03-22T15:50:50+00:00","dateModified":"2022-04-28T12:14:34+00:00","breadcrumb":{"@id":"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/emission-2022\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/emission-2022\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/emission-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.egetis.com\/sv\/"},{"@type":"ListItem","position":2,"name":"Investerare","item":"https:\/\/www.egetis.com\/sv\/investerare\/"},{"@type":"ListItem","position":3,"name":"Nyemissioner","item":"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/"},{"@type":"ListItem","position":4,"name":"Emission 2022"}]},{"@type":"WebSite","@id":"https:\/\/www.egetis.com\/sv\/#website","url":"https:\/\/www.egetis.com\/sv\/","name":"Egetis Therapeutics","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.egetis.com\/sv\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"}]}},"_links":{"self":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/pages\/7654","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/comments?post=7654"}],"version-history":[{"count":0,"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/pages\/7654\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/pages\/5170"}],"wp:attachment":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/media?parent=7654"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}},{"id":7646,"date":"2022-03-22T16:42:53","date_gmt":"2022-03-22T15:42:53","guid":{"rendered":"https:\/\/www.egetis.com\/?page_id=7646"},"modified":"2024-10-27T21:53:20","modified_gmt":"2024-10-27T20:53:20","slug":"emission-2020","status":"publish","type":"page","link":"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/emission-2020\/","title":{"rendered":"Emission 2020"},"content":{"rendered":"<p><a href=\"https:\/\/www.egetis.com\/wp-content\/uploads\/Prospekt-PledPharma-2020-11-05.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Prospekt nyemission 201105<\/a><\/p>\n<p><a href=\"https:\/\/www.egetis.com\/wp-content\/uploads\/Tillaggsprospekt-.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Till\u00e4gg till prospekt avseende nyemission 201112<\/a><\/p>\n<p><a href=\"https:\/\/www.egetis.com\/wp-content\/uploads\/Noteringsprospekt_PledPharma.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Prospekt avseende upptagande till handel p\u00e5 Nasdaq Stockholm<\/a> (.pdf)<\/p>\n<h4>Det f\u00f6rv\u00e4rvade bolaget Rare Thyroid Therapeutics \u00e5rsredovisningar<\/h4>\n<p><a href=\"https:\/\/www.egetis.com\/wp-content\/uploads\/RTT_AR_2019.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Rare Thyroid Therapeutics \u00e5rsredovisning 2019<\/a><br \/>\n<a href=\"https:\/\/www.egetis.com\/wp-content\/uploads\/RTT_AR_2018.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Rare Thyroid Therapeutics \u00e5rsredovisning 2018<\/a><br \/>\n<a href=\"https:\/\/www.egetis.com\/wp-content\/uploads\/MND_AR_2017.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">MN Development \u00e5rsredovisning 2017<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Prospekt nyemission 201105 Till\u00e4gg till prospekt avseende nyemission 201112 Prospekt avseende upptagande till handel p\u00e5 Nasdaq Stockholm (.pdf) Det f\u00f6rv\u00e4rvade bolaget Rare Thyroid Therapeutics \u00e5rsredovisningar Rare Thyroid Therapeutics \u00e5rsredovisning 2019 Rare Thyroid Therapeutics \u00e5rsredovisning 2018 MN Development \u00e5rsredovisning 2017<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":5170,"menu_order":27,"comment_status":"closed","ping_status":"closed","template":"modular-finance-moduler.php","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-7646","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Emission 2020 - Egetis Therapeutics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/emission-2020\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Emission 2020 - Egetis Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Prospekt nyemission 201105 Till\u00e4gg till prospekt avseende nyemission 201112 Prospekt avseende upptagande till handel p\u00e5 Nasdaq Stockholm (.pdf) Det f\u00f6rv\u00e4rvade bolaget Rare Thyroid Therapeutics \u00e5rsredovisningar Rare Thyroid Therapeutics \u00e5rsredovisning 2019 Rare Thyroid Therapeutics \u00e5rsredovisning 2018 MN Development \u00e5rsredovisning 2017\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/emission-2020\/\" \/>\n<meta property=\"og:site_name\" content=\"Egetis Therapeutics\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-27T20:53:20+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/emission-2020\/\",\"url\":\"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/emission-2020\/\",\"name\":\"Emission 2020 - Egetis Therapeutics\",\"isPartOf\":{\"@id\":\"https:\/\/www.egetis.com\/sv\/#website\"},\"datePublished\":\"2022-03-22T15:42:53+00:00\",\"dateModified\":\"2024-10-27T20:53:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/emission-2020\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/emission-2020\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/emission-2020\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\/\/www.egetis.com\/sv\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Investerare\",\"item\":\"https:\/\/www.egetis.com\/sv\/investerare\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nyemissioner\",\"item\":\"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Emission 2020\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.egetis.com\/sv\/#website\",\"url\":\"https:\/\/www.egetis.com\/sv\/\",\"name\":\"Egetis Therapeutics\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.egetis.com\/sv\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Emission 2020 - Egetis Therapeutics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/emission-2020\/","og_locale":"sv_SE","og_type":"article","og_title":"Emission 2020 - Egetis Therapeutics","og_description":"Prospekt nyemission 201105 Till\u00e4gg till prospekt avseende nyemission 201112 Prospekt avseende upptagande till handel p\u00e5 Nasdaq Stockholm (.pdf) Det f\u00f6rv\u00e4rvade bolaget Rare Thyroid Therapeutics \u00e5rsredovisningar Rare Thyroid Therapeutics \u00e5rsredovisning 2019 Rare Thyroid Therapeutics \u00e5rsredovisning 2018 MN Development \u00e5rsredovisning 2017","og_url":"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/emission-2020\/","og_site_name":"Egetis Therapeutics","article_modified_time":"2024-10-27T20:53:20+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/emission-2020\/","url":"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/emission-2020\/","name":"Emission 2020 - Egetis Therapeutics","isPartOf":{"@id":"https:\/\/www.egetis.com\/sv\/#website"},"datePublished":"2022-03-22T15:42:53+00:00","dateModified":"2024-10-27T20:53:20+00:00","breadcrumb":{"@id":"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/emission-2020\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/emission-2020\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/emission-2020\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.egetis.com\/sv\/"},{"@type":"ListItem","position":2,"name":"Investerare","item":"https:\/\/www.egetis.com\/sv\/investerare\/"},{"@type":"ListItem","position":3,"name":"Nyemissioner","item":"https:\/\/www.egetis.com\/sv\/investerare\/prospekt\/"},{"@type":"ListItem","position":4,"name":"Emission 2020"}]},{"@type":"WebSite","@id":"https:\/\/www.egetis.com\/sv\/#website","url":"https:\/\/www.egetis.com\/sv\/","name":"Egetis Therapeutics","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.egetis.com\/sv\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"}]}},"_links":{"self":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/pages\/7646","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/comments?post=7646"}],"version-history":[{"count":0,"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/pages\/7646\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/pages\/5170"}],"wp:attachment":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/media?parent=7646"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}},{"id":7460,"date":"2021-12-17T17:28:49","date_gmt":"2021-12-17T16:28:49","guid":{"rendered":"https:\/\/www.egetis.com\/?page_id=7460"},"modified":"2021-12-17T17:29:14","modified_gmt":"2021-12-17T16:29:14","slug":"karriar","status":"publish","type":"page","link":"https:\/\/www.egetis.com\/sv\/karriar\/","title":{"rendered":"Karri\u00e4r"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":1000012,"comment_status":"closed","ping_status":"closed","template":"career.php","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-7460","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Karri\u00e4r - Egetis Therapeutics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.egetis.com\/sv\/karriar\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Karri\u00e4r - Egetis Therapeutics\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.egetis.com\/sv\/karriar\/\" \/>\n<meta property=\"og:site_name\" content=\"Egetis Therapeutics\" \/>\n<meta property=\"article:modified_time\" content=\"2021-12-17T16:29:14+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.egetis.com\/sv\/karriar\/\",\"url\":\"https:\/\/www.egetis.com\/sv\/karriar\/\",\"name\":\"Karri\u00e4r - Egetis Therapeutics\",\"isPartOf\":{\"@id\":\"https:\/\/www.egetis.com\/sv\/#website\"},\"datePublished\":\"2021-12-17T16:28:49+00:00\",\"dateModified\":\"2021-12-17T16:29:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.egetis.com\/sv\/karriar\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.egetis.com\/sv\/karriar\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.egetis.com\/sv\/karriar\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\/\/www.egetis.com\/sv\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Karri\u00e4r\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.egetis.com\/sv\/#website\",\"url\":\"https:\/\/www.egetis.com\/sv\/\",\"name\":\"Egetis Therapeutics\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.egetis.com\/sv\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Karri\u00e4r - Egetis Therapeutics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.egetis.com\/sv\/karriar\/","og_locale":"sv_SE","og_type":"article","og_title":"Karri\u00e4r - Egetis Therapeutics","og_url":"https:\/\/www.egetis.com\/sv\/karriar\/","og_site_name":"Egetis Therapeutics","article_modified_time":"2021-12-17T16:29:14+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.egetis.com\/sv\/karriar\/","url":"https:\/\/www.egetis.com\/sv\/karriar\/","name":"Karri\u00e4r - Egetis Therapeutics","isPartOf":{"@id":"https:\/\/www.egetis.com\/sv\/#website"},"datePublished":"2021-12-17T16:28:49+00:00","dateModified":"2021-12-17T16:29:14+00:00","breadcrumb":{"@id":"https:\/\/www.egetis.com\/sv\/karriar\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.egetis.com\/sv\/karriar\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.egetis.com\/sv\/karriar\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.egetis.com\/sv\/"},{"@type":"ListItem","position":2,"name":"Karri\u00e4r"}]},{"@type":"WebSite","@id":"https:\/\/www.egetis.com\/sv\/#website","url":"https:\/\/www.egetis.com\/sv\/","name":"Egetis Therapeutics","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.egetis.com\/sv\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"}]}},"_links":{"self":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/pages\/7460","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/comments?post=7460"}],"version-history":[{"count":0,"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/pages\/7460\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/media?parent=7460"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}},{"id":7375,"date":"2021-10-28T11:05:02","date_gmt":"2021-10-28T09:05:02","guid":{"rendered":"https:\/\/www.egetis.com\/pipeline\/managed-access-policy\/"},"modified":"2021-10-29T09:37:18","modified_gmt":"2021-10-29T07:37:18","slug":"managed-access-policy","status":"publish","type":"page","link":"https:\/\/www.egetis.com\/sv\/pipeline\/managed-access-policy\/","title":{"rendered":"Managed Access Policy"},"content":{"rendered":"<p>Egetis Therapeutics purpose is to create value for patients, society and shareholder by developing and providing a portfolio of unique products for the treatment of rare diseases with substantial unmet medical need.<\/p>\n<p>Patients with serious or life-threatening diseases or conditions sometimes seek medical products that are not yet approved. Egetis Therapeutics \u201cManaged Access\u201d program addresses this need by making certain investigational or unapproved treatments available to eligible patients. Below you\u2019ll find additional details about this program.<\/p>\n<h4><strong>Product evaluation in clinical trials<\/strong><\/h4>\n<p>Before a product can be placed on the market, it must undergo well-controlled clinical trials to prove that it is safe and effective, and its potential benefit to patients outweighs the possible risks. Clinical trial results and related product information are then submitted to the relevant health authorities for review. Clinical trials result in the generation of evidence that may lead to the approval of a product, which can make it more widely available to patients.<\/p>\n<h4><strong>What is Egetis Managed Access program?<\/strong><\/h4>\n<p>There are instances where a patient has a serious or life-threatening disease or condition, for which all currently available treatment options have been exhausted and enrolment into a clinical trial is not possible. In these cases, the treating physician can request access to an investigational product prior to regulatory approval, provided it is allowed by the applicable local legislations. Within Egetis, we refer to such provision of an investigational product as \u201cManaged Access\u201d.<\/p>\n<p>The Egetis \u201cManaged Access\u201d terminology covers all locally defined pre-approval access mechanisms and programs such as \u201cCompassionate Use\u201d, \u201cExpanded Access\u201d, \u201cNamed Patient Supply\u201d, \u201cSpecial Access Schemes\/Programs\u201d, \u201cAutorisations temporaires d\u2019utilisation (ATU)\u201d and others.<\/p>\n<h4><strong>Who is eligible for Egetis Managed Access program? <\/strong><\/h4>\n<p>Egetis considers granting managed access to investigational products when all of the following criteria are met:<\/p>\n<ul>\n<li>The patient to be treated has a serious or life-threatening disease or condition, and no comparable or satisfactory alternative therapy is available to monitor or treat the disease or condition, alternatively that the patient meets any other important medical criteria established by the medical experts working on the product development program;<\/li>\n<li>The patient is ineligible for enrolment into or unable to access ongoing clinical trials;<\/li>\n<li>Sufficient data exists to believe the potential benefit of treatment outweighs the potential risk in the context of the disease or condition to be treated;<\/li>\n<li>Egetis has an adequate supply of the investigational product and providing the investigational product will not interfere with ongoing clinical trial(s) or with the overall development program;<\/li>\n<li>Such access provision is allowed as per local laws and regulations.<\/li>\n<\/ul>\n<p>Information on ongoing Clinical Trials are available at <a href=\"http:\/\/www.clinicaltrials.gov\">www.clinicaltrials.gov<\/a><\/p>\n<h4><strong>How do I submit a request for Managed Access? <\/strong><\/h4>\n<p>A request must be submitted by the treating physician on behalf of the patient. Requests can be submitted via email to <a href=\"mailto:managed.access@egetis.com\">managed.access@egetis.com<\/a><\/p>\n<h4><strong>How are requests evaluated?<\/strong><\/h4>\n<p>Each request will be acknowledged immediately and reviewed carefully and fairly by the appropriate Egetis medical team with every effort made to provide a response promptly once we have all the necessary information.<\/p>\n<p>Please note that your request will be assessed in consideration of applicable local laws and regulations.<\/p>\n<p>For Managed Access related questions, health care professionals can contact the Egetis medical team at <a href=\"mailto:managed.access@egetis.com\">managed.access@egetis.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Egetis Therapeutics purpose is to create value for patients, society and shareholder by developing and providing a portfolio of unique products for the treatment of rare diseases with substantial unmet medical need. Patients with serious or life-threatening diseases or conditions sometimes seek medical products that are not yet approved. Egetis Therapeutics \u201cManaged Access\u201d program addresses [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"parent":163,"menu_order":57,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-7375","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Managed Access Policy - Egetis Therapeutics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.egetis.com\/sv\/pipeline\/managed-access-policy\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Managed Access Policy - Egetis Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Egetis Therapeutics purpose is to create value for patients, society and shareholder by developing and providing a portfolio of unique products for the treatment of rare diseases with substantial unmet medical need. Patients with serious or life-threatening diseases or conditions sometimes seek medical products that are not yet approved. Egetis Therapeutics \u201cManaged Access\u201d program addresses [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.egetis.com\/sv\/pipeline\/managed-access-policy\/\" \/>\n<meta property=\"og:site_name\" content=\"Egetis Therapeutics\" \/>\n<meta property=\"article:modified_time\" content=\"2021-10-29T07:37:18+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.egetis.com\/sv\/pipeline\/managed-access-policy\/\",\"url\":\"https:\/\/www.egetis.com\/sv\/pipeline\/managed-access-policy\/\",\"name\":\"Managed Access Policy - Egetis Therapeutics\",\"isPartOf\":{\"@id\":\"https:\/\/www.egetis.com\/sv\/#website\"},\"datePublished\":\"2021-10-28T09:05:02+00:00\",\"dateModified\":\"2021-10-29T07:37:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.egetis.com\/sv\/pipeline\/managed-access-policy\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.egetis.com\/sv\/pipeline\/managed-access-policy\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.egetis.com\/sv\/pipeline\/managed-access-policy\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\/\/www.egetis.com\/sv\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pipeline\",\"item\":\"https:\/\/www.egetis.com\/sv\/pipeline\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Managed Access Policy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.egetis.com\/sv\/#website\",\"url\":\"https:\/\/www.egetis.com\/sv\/\",\"name\":\"Egetis Therapeutics\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.egetis.com\/sv\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Managed Access Policy - Egetis Therapeutics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.egetis.com\/sv\/pipeline\/managed-access-policy\/","og_locale":"sv_SE","og_type":"article","og_title":"Managed Access Policy - Egetis Therapeutics","og_description":"Egetis Therapeutics purpose is to create value for patients, society and shareholder by developing and providing a portfolio of unique products for the treatment of rare diseases with substantial unmet medical need. Patients with serious or life-threatening diseases or conditions sometimes seek medical products that are not yet approved. Egetis Therapeutics \u201cManaged Access\u201d program addresses [&hellip;]","og_url":"https:\/\/www.egetis.com\/sv\/pipeline\/managed-access-policy\/","og_site_name":"Egetis Therapeutics","article_modified_time":"2021-10-29T07:37:18+00:00","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"3 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.egetis.com\/sv\/pipeline\/managed-access-policy\/","url":"https:\/\/www.egetis.com\/sv\/pipeline\/managed-access-policy\/","name":"Managed Access Policy - Egetis Therapeutics","isPartOf":{"@id":"https:\/\/www.egetis.com\/sv\/#website"},"datePublished":"2021-10-28T09:05:02+00:00","dateModified":"2021-10-29T07:37:18+00:00","breadcrumb":{"@id":"https:\/\/www.egetis.com\/sv\/pipeline\/managed-access-policy\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.egetis.com\/sv\/pipeline\/managed-access-policy\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.egetis.com\/sv\/pipeline\/managed-access-policy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.egetis.com\/sv\/"},{"@type":"ListItem","position":2,"name":"Pipeline","item":"https:\/\/www.egetis.com\/sv\/pipeline\/"},{"@type":"ListItem","position":3,"name":"Managed Access Policy"}]},{"@type":"WebSite","@id":"https:\/\/www.egetis.com\/sv\/#website","url":"https:\/\/www.egetis.com\/sv\/","name":"Egetis Therapeutics","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.egetis.com\/sv\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"}]}},"_links":{"self":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/pages\/7375","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/comments?post=7375"}],"version-history":[{"count":0,"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/pages\/7375\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/pages\/163"}],"wp:attachment":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/media?parent=7375"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}]